AGL 38.89 Increased By ▲ 0.87 (2.29%)
AIRLINK 206.39 Increased By ▲ 9.03 (4.58%)
BOP 9.51 Decreased By ▼ -0.03 (-0.31%)
CNERGY 6.01 Increased By ▲ 0.10 (1.69%)
DCL 8.91 Increased By ▲ 0.09 (1.02%)
DFML 37.60 Increased By ▲ 1.86 (5.2%)
DGKC 96.90 Increased By ▲ 0.04 (0.04%)
FCCL 35.30 Increased By ▲ 0.05 (0.14%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.48 Increased By ▲ 0.31 (2.35%)
HUBC 127.94 Increased By ▲ 0.39 (0.31%)
HUMNL 13.70 Increased By ▲ 0.20 (1.48%)
KEL 5.40 Increased By ▲ 0.08 (1.5%)
KOSM 7.14 Increased By ▲ 0.14 (2%)
MLCF 44.00 Decreased By ▼ -0.70 (-1.57%)
NBP 60.25 Decreased By ▼ -1.17 (-1.9%)
OGDC 215.99 Increased By ▲ 1.32 (0.61%)
PAEL 40.52 Increased By ▲ 1.73 (4.46%)
PIBTL 8.37 Increased By ▲ 0.12 (1.45%)
PPL 194.50 Increased By ▲ 1.42 (0.74%)
PRL 39.27 Increased By ▲ 0.61 (1.58%)
PTC 26.68 Increased By ▲ 0.88 (3.41%)
SEARL 106.50 Increased By ▲ 2.90 (2.8%)
TELE 8.61 Increased By ▲ 0.31 (3.73%)
TOMCL 36.10 Increased By ▲ 1.10 (3.14%)
TPLP 13.80 Increased By ▲ 0.50 (3.76%)
TREET 24.38 Increased By ▲ 2.22 (10.02%)
TRG 61.15 Increased By ▲ 5.56 (10%)
UNITY 32.95 Decreased By ▼ -0.02 (-0.06%)
WTL 1.67 Increased By ▲ 0.07 (4.38%)
BR100 11,922 Increased By 195.1 (1.66%)
BR30 36,781 Increased By 404.5 (1.11%)
KSE100 111,730 Increased By 2217.2 (2.02%)
KSE30 35,224 Increased By 710.3 (2.06%)
World

Moderna files for US authorization to use its COVID-19 vaccine in teens

  • Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18.
Published June 10, 2021

Moderna Inc said on Thursday it has filed for US authorization to use its COVID-19 vaccine in adolescents aged 12 to 18, the latest company to seek approval to help expand the inoculation drive in the country.

Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18. The drugmaker has already submitted applications to the European and Canadian health regulators seeking authorization for the vaccine's use in adolescents.

Moderna's two-shot vaccine last month was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial which evaluated the vaccine in 3,732 teenagers.

Vaccinating children has been considered key to achieving "herd immunity" and the US has already authorized Pfizer and German partner BioNTech SE's COVID-19 vaccine for use in children as young as 12.

Comments

Comments are closed.